Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K van Besien

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Bone Marrow Transplantation|April 21, 2001
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survivalK van Besien, A Rodriguez, S Tomany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2007
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804N L Bartlett, D Niedzwiecki, J L Johnson, et al.
Bone Marrow Transplantation|May 7, 2003
Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovirA Verma, S Devine, M Morrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1989
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantationC R Nichols, G Tricot, S D Williams, et al.
Experimental Hematology|August 1, 1990
Characteristics of engraftment after repeated autologous bone marrow transplantationK van Besien, C R Nichols, G Tricot, et al.
Blood|October 1, 1995
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host diseaseM Körbling, Y O Huh, A Durett, et al.
Bone Marrow Transplantation|August 28, 2003
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignanciesK Van Besien, S Devine, A Wickrema, et al.
European Journal of Gynaecological Oncology|January 1, 1997
Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literatureS Piamsomboon, A P Kudelka, W Termrungruanglert, et al.
Bone Marrow Transplantation|June 18, 1999
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemiaD Przepiorka, I Khouri, P Thall, et al.
Bone Marrow Transplantation|May 24, 2016
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging taskS R Marino, S M Lee, T A Binkowski, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|April 21, 2001
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survivalK van Besien, A Rodriguez, S Tomany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2007
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804N L Bartlett, D Niedzwiecki, J L Johnson, et al.
Bone Marrow Transplantation|May 7, 2003
Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovirA Verma, S Devine, M Morrow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1989
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantationC R Nichols, G Tricot, S D Williams, et al.
Experimental Hematology|August 1, 1990
Characteristics of engraftment after repeated autologous bone marrow transplantationK van Besien, C R Nichols, G Tricot, et al.
Blood|October 1, 1995
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host diseaseM Körbling, Y O Huh, A Durett, et al.
Bone Marrow Transplantation|August 28, 2003
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignanciesK Van Besien, S Devine, A Wickrema, et al.
European Journal of Gynaecological Oncology|January 1, 1997
Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literatureS Piamsomboon, A P Kudelka, W Termrungruanglert, et al.
Bone Marrow Transplantation|June 18, 1999
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemiaD Przepiorka, I Khouri, P Thall, et al.
Bone Marrow Transplantation|May 24, 2016
Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging taskS R Marino, S M Lee, T A Binkowski, et al.
Pageof 8